Intermountain Healthcare Inks Taiwanese Distribution Deal for NGS Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – US provider Intermountain Healthcare has signed a distribution deal allowing Taiwan's Prisma Biotech to sell the ICG100 tumor sequencing test in that country.

The next-generation sequencing-based ICG100 test provides analyzes 100 genes for patient-specific mutations that could suggest personalized drug treatments. Intermountain controls the rights to the next-generation sequencing-based test through a contract with Prisma's fully-owned subsidiary, ReadGene.

Financial and other details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.

Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.